articleTop 1% cited

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Neurology · 2003 · Vol. 61(1) · pp. 46–54

J. M. Orgogozo✉S. GilmanJean‐François DartiguesB. LaurentMichèle PuelL. KirbyP. JouannyBruno DuboisLarry S. EisnerStephen FlitmanBernard‐François MichelMerçé Boada(Fundació ACE)Ana Frank(Hospital Universitario La Paz)C. Hock

View via DOI Publisher page

Abstract

Postvaccination meningoencephalitis occurred without clear relation to serum anti-Abeta42 antibody titers. Potential mechanisms such as T-cell and microglial activation may be responsible and are under consideration to develop a safer anti-Abeta immunotherapy for AD.

Alzheimer's disease research and treatments Machine Learning in Bioinformatics Neuroinflammation and Neurodegeneration MechanismsTolerabilityMedicineMeningoencephalitisPlaceboAdjuvantInternal medicineImmunizationGastroenterologyAdverse effectAntibody

MeSH terms

Adrenal Cortex HormonesAgedAged, 80 and overAlzheimer DiseaseAntibodiesBrainEuropeFemaleHumansMagnetic Resonance ImagingMaleMeningoencephalitisMiddle AgedNeuropsychological TestsPeptide Fragments

Citations

1,336

FWCI

35.43

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial